As Covid-re­lat­ed chal­lenges weigh on pa­tient re­cruit­ment, biotech scraps PhI­Ib/III Parkin­son's pro­gram

More than two years af­ter lit­tle Swiss biotech Ad­dex Ther­a­peu­tics post­poned a Phase IIb/III tri­al in­def­i­nite­ly due to the then-nascent Covid-19 pan­dem­ic, it’s throw­ing in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER